Centre Hospitalier Universitaire De Nantes — Sponsor Intelligence | 196 EU Trials

Filter these 196 trials by condition, phase, country and more.

Open in Search →

196 Registered trials

101 Recruiting

50 Completed trials

7 Countries active

292 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 54 Phase II/III: 10 Phase II: 70 Phase I/II: 8 Phase III/IV: 8 Phase IV: 29 Phase I: 3 Phase I (Other): 7 Phase I (FiH): 6 Other: 1

Oversight events:

1 serious breach 7 temporary halts 1 urgent safety measure 1 corrective measure across 10 trials

View oversight register →

100%

50 of 50 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Asthma 3 Hepatocellular carcinoma 3 Parkinson's disease 2 Chronic kidney disease 2 Vitiligo 2 Alcohol use disorder 2 Epidermolysis bullosa 2 Cerebral haemorrhage 1 Colorectal cancer metastatic 1 Endometriosis 1 Hepatectomy 1 Intensive care 1

Top IMPs

SODIUM CHLORIDE 9 TACROLIMUS 5 MYCOPHENOLATE MOFETIL 4 PSILOCYBINE 4 AMOXICILLIN, CLAVULANIC ACID 3 BORTEZOMIB 3 CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS 3 ISATUXIMAB 3 KETAMINE HYDROCHLORIDE 3 LENALIDOMIDE 3 MYCOPHENOLIC ACID 3 N,N-DIETHYL-(2-(4-(2-(18F)FLUOROETHOXY)PHENYL)-5,7-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDINE-3-YL)ACETAMIDE 3

All trials — page 2

196 total

Efficacy and safety of Remimazolam compared to Ketamine and Propofol in Rapid Sequence Induction. A monocentric pilot randomised-controlled … Pending

2025-521602-18-00 Phase II 1 country REMIMAZOLAM
DOSABEMA-Pharmacokinetic model of abemaciclib: correlation with severe diarrhea as the primary toxicity endpoint in patients with hormone re… Pending

2025-521696-31-00 Phase IV 1 country ABEMACICLIB
Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage. Pending

2025-521923-58-00 Phase II 1 country N,N-DIETHYL-(2-(4-(2-(18F)FLUOROETHOXY)PHENYL)-5,7-DIMETHYLPYRAZOLO(1,5-A)PYRIMI…
Effect of Empagliflozin in patients with eGFR between 10 and 20 ml/min/1.73m2 - EMPA [10-20] Pending

2025-522119-41-00 Phase III 1 country EMPAGLIFLOZIN
Study comparing two dosing methods of tocilizumab in patients with rheumatoid arthritis in remission or with low disease activity Pending

2025-522319-41-00 Phase IV 1 country TOCILIZUMAB
ILHEP : Effect of perioperative Intravenous Lidocaine on postoperative opioid related-side effects after open HEPatectomy: a multicentre pro… Pending

2025-522462-73-00 Phase IV 1 country
Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a pilot study Pending

2025-522743-18-00 Phase II 1 country DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL; HYP…
Upadacitinib in adult patients with erosive mucosal Lichen Planus and Lichen Planopilaris. Pending

2025-522870-35-00 Phase II 1 country UPADACITINIB
Women victims of violences : PTSD treatment by traumatic memory reactivation under the influence of propranolol (VIOFEM) Pending

2025-523107-30-01 Phase III 1 country PROPRANOLOL HYDROCHLORIDE
Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac a… Pending

2025-523616-36-00 Phase II 1 country (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHY…
Study of 18FET PET in functional pituitary adenomas with indeterminate MRI findings Pending

2025-523829-17-00 Phase II 1 country FLUOROETHYLTYROSINE F-18
OFA-VATS : Impact of opioid free anesthesia on postoperative quality of recovery and analgesia after video or robot assisted thoracic surger… Pending

2025-524240-35-00 Phase III/IV 1 country
Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms Pending

2025-524344-35-00 Phase III 1 country ACETAZOLAMIDE
Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes Pending

2025-524395-30-00 Phase IV 1 country
Mitochondrial network modulation approach using hyperbaric oxygen (HBO) therapy and NNbUVB for treating vitiligo Pending

2025-524709-34-00 Phase II 1 country OXYGEN
Single-centre Phase I/II study with dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy in patients w… Pending

2025-524725-41-00 Phase I (Other) 1 country
IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO) Pending

2025-524834-24-00 Phase I/II 1 country ANAKINRA; ETANERCEPT; MYCOPHENOLIC ACID; TACROLIMUS
Analysis of the performance of PSMA emission tomography in patients with prostate cancer treated with HIFU Pending

2026-525181-22-00 Phase IV 1 country
Pilot study comparing the efficacy of intra-articular glenohumeral injection combined with suprascapular nerve block versus intra-articular … Pending

2026-525317-31-00 Phase II 1 country BETAMETHASONE DIPROPIONATE, BETAMETHASONE SODIUM PHOSPHATE
Intravenous iron in the management of drug-resistant restless legs syndrome Pending

2026-525613-31-00 Phase II 1 country
Methotrexate treatment in hand osteoarthritis refractory to usual treatments Recruiting

2022-502362-24-00 Phase II 1 country FOLIC ACID; METHOTREXATE
Prospective pilot study of L-dopa treatment in patients with a neurodevelopmental disorder linked to a pathogenic variant of the CTNNB1 gene Recruiting

2024-514852-34-01 Phase II 1 country CARBIDOPA; LEVODOPA
Evaluation of long-term safety in parkinsonian patients with intracerebroventricular administration of A-dopamine (anaerobic dopamine) - (DI… Recruiting

2025-522261-30-00 Phase I (FiH) 1 country
Impact of dapagliflozin for the regulation of immunological activity in Membranous Nephropathy Recruiting

2023-507658-34-00 Phase II/III 1 country DAPAGLIFLOZIN

Showing 25–48 of 196 trials

← All sponsors A–Z